Silence Therapeutics (SLN) Short-term Investments (2020 - 2026)

Silence Therapeutics has disclosed Short-term Investments across 5 years of filings, most recently posting $64.4 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $64.4 million, down 10.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $64.4 million (down 10.09% YoY), and the FY2025 annual result was $73.8 million, up 14.05% from the prior year.
• Short-term Investments came in at $64.4 million for Q1 2026 at Silence Therapeutics, down from $73.8 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $73.8 million in Q4 2025 to a low of $20.2 million in Q3 2025.
• The 4-year median for Short-term Investments is $64.7 million (2024), against an average of $57.7 million.
• Across the five-year window, Short-term Investments surged 75.11% in 2024 and decreased 10.09% in 2026, its largest moves.
• Silence Therapeutics' Short-term Investments stood at $37.0 million in 2023, then soared by 75.11% to $64.7 million in 2024, then gained by 14.05% to $73.8 million in 2025, then declined by 12.75% to $64.4 million in 2026.
• The last three Short-term Investments figures came in at $64.4 million (Q1 2026), $73.8 million (Q4 2025), and $20.2 million (Q3 2025), per Business Quant data.